Claims:

1. Use of a microbubble-chemotherapeutic agent complex in the manufacture of a medicament for use in the treatment of cancer via sonodynamic therapy, wherein said sonodynamic therapy comprises simultaneous or sequential use of a microbubble-sonosensitiser complex.

2. Use of a microbubble-chemotherapeutic agent complex in the manufacture of a medicament for use in the treatment of cancer via sonodynamic therapy, wherein said complex is additionally attached to or associated with at least one sonosensitiser.

3. Use as claimed in claim 2, wherein said complex is attached to or associated with at least one sonosensitiser via a non-covalent linkage.

4. Use as claimed in claim 3, wherein said non-covalent linkage is a biotin-avidin interaction.

5. Use as claimed in claim 1, wherein the microbubble-chemotherapeutic agent complex comprises a microbubble attached to or associated with at least one chemotherapeutic agent.

6. Use as claimed in claim 5, wherein the microbubble-chemotherapeutic agent complex comprises a microbubble attached to or associated with at least one chemotherapeutic agent via a non-covalent linkage.

7. Use as claimed in claim 6, wherein said non-covalent linkage is a biotin-avidin interaction.

8. Use as claimed in any one of claims 1 to 7, wherein the microbubble-chemotherapeutic agent complex comprises a microbubble having a shell which retains a gas.

9. Use as claimed in claim 8, wherein said gas is oxygen.

10. Use as claimed in any one of claims 1 and 5 to 9, wherein the microbubble-sonosensitiser complex comprises a microbubble having a shell which retains a gas.

11. Use as claimed in claim 10, wherein said gas is oxygen.

12. Use as claimed in any preceding claim, wherein said microbubble-chemotherapeutic agent complex and/or said microbubble-sonosensitiser complex comprises a microbubble having a diameter in the range 0.5 to 100μm.

13. Use as claimed in any preceding claim, wherein said microbubble-chemotherapeutic agent complex and/or said microbubble-sonosensitiser complex comprises a phospholipid monolayer shell having linked thereto one or more polymers.

14. Use as claimed in any one of the preceding claims, wherein the sonosensitiser is selected from phenothiazine dyes, porphyrins, chlorins, benzochlorins, phthalocyanines, napthalocyanines, porphycenes, cyanines and cyanine analogues, azodipyromethines, acridine dyes, purpurins, pheophorbides, verdins, psoralens, hematoporphyrins, protoporphyrins and curcumins.

15. Use as claimed in claim 14, wherein the sonosensitiser is Rose Bengal, methylene blue, indocyanine green or an analogue of indocyanine green.

16. A pharmaceutical composition comprising a microbubble-chemotherapeutic agent complex as defined in any one of claims 2 to 4, together with at least one pharmaceutical carrier or excipient, optionally wherein said microbubble-

chemotherapeutic agent complex is further defined as in any one of claims 8, 9 and 12 to 15.

17. A pharmaceutical composition as claimed in claim 16, wherein said microbubble-chemotherapeutic agent complex comprises a microbubble having non-covalently bound thereto at least one chemotherapeutic agent and at least one sonosensitiser.

18. A pharmaceutical composition comprising a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13, and a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 15, together with at least one pharmaceutical carrier or excipient.

19. Use of a pharmaceutical composition as claimed in any one of claims 16 to 18 in the manufacture of a medicament for use in a method of treating cancer via sonodynamic therapy.

20. Use as claimed in claim 19 in a method of treating cancer via sonodynamic therapy and simultaneous diagnostic imaging of cancer.

21. Use as claimed in claim 19 or claim 20 in which said composition is contacted with cells or tissues of a patient and, either simultaneously or sequentially, said cells or tissues are subjected to irradiation with ultrasound and/or light.

22. Use of a pharmaceutical composition as claimed in any one of claims 19 to 21 in the treatment and/or diagnosis of deep-sited tumours.

23. Use as claimed in any one of claims 19 to 22 wherein said cancer is selected from the group consisting of sarcomas, including osteogenic and soft tissue sarcomas, carcinomas, lymphomas, including Hodgkin and non-Hodgkin lymphomas, neuroblastoma, melanoma, myeloma, Wilm's tumour, and leukemias,

including acute lymphoblastic leukaemia and acute myeloblastic leukaemia, astrocytomas, gliomas and retinoblastomas.

24. Use as claimed in claim 23, wherein said cancer is breast, lung, cerebral, bladder, thyroid, prostate, colon, rectum, pancreas, stomach, liver, uterine, hepatic, renal, prostate, cervical or ovarian carcinoma.

25. Use as claimed in claim 23, wherein said cancer is pancreatic cancer.

26. Use of a product comprising a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13, and a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 15 in the manufacture of a medicament for simultaneous or sequential use in a method of treating cancer via sonodynamic therapy.

27. A kit comprising the following components: (i) a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13; and separately (ii) a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 15; optionally together with (iii) instructions for the use of said components in a method of treating cancer via sonodynamic therapy.

28. Use of a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 15 in the manufacture of a medicament for use in the treatment of cancer via sonodynamic therapy, wherein said sonodynamic therapy comprises simultaneous or sequential use of a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13.

29. Use as claimed in claim 1 or claim 28 in a method of treating cancer via sonodynamic therapy and simultaneous diagnostic imaging of cancer.

30. A microbubble having linked thereto at least one chemotherapeutic agent and at least one sonosensitiser.

31. A microbubble as claimed in claim 30 which contains oxygen gas.